7 percent fewer days supply of brand OHAs compared to FBDE recipients (114 vs.
The number of generic fills was 11 percent higher among FBDE recipients compared to non-LIS beneficiaries (8.
90 for generics by FBDE and non-FB recipients, respectively, and $147.
The overall cost of OHA therapy for non-LIS beneficiaries was 28 percent below that of FBDE recipients ($656.
For example, the unadjusted difference in annual brand days supply between FBDE and non-FB recipients of 15 days (already a small difference) was reduced to 7 days after adjustment.
Diabetes severity and comorbidity measures were highest for FBDE recipients and lowest for non-LIS beneficiaries.